


Vaccine Induced Thrombocytopenia/Thrombosis in COVID-19

April 2021—Version 1.0

VITT is a potential RARE complication occurring within 4-28 day of receiving the Janssen/Johnson & Johnson* or AstraZeneca* COVID-19 vaccine (not available in the US) *both are adenoviral vector vaccines. Risk is not associated with the Pfizer or Moderna mRNA vaccines

- Has been described in young (18-48 years) women
- Mimics autoimmune heparin induced thrombocytopenia (prior exposure to heparin not needed)
- Thrombosis includes cerebral venous sinus thrombosis (CVST), but thrombosis at other sites may also be present
- **From the CDC: “do not treat patients with thrombotic events and thrombocytopenia following receipt of Janssen [Johnson & Johnson] COVID-19 vaccine with heparin, unless HIT testing is negative”**





References:

1. [CDC – Reports of cerebral venous sinus thrombosis with thrombocytopenia after Janseen COVID-19 vaccine. Advisory Committee on Immunization Practices \(ACIP\). April 14th, 2021](#)
2. Ferro, José M., et al. "European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis—endorsed by the European Academy of Neurology." *European stroke journal* 2.3 (2017): 195-221
3. Heldner, Mirjam R., et al. "Prediction of cerebral venous thrombosis with a new clinical score and D-dimer levels." *Neurology* 95.7 (2020): e898-e909
4. Spadaro, Anthony, et al. "Cerebral venous thrombosis: Diagnosis and management in the emergency department setting." *The American Journal of Emergency Medicine* (2021)

COVID-19 WORKGROUP FOR THE ACUTE MEDICINE CLINICAL PRACTICE COUNCIL

This team represents expertise in COVID-19. If you would like further information, please contact the work group lead, Cameron Berg, cameronberg@northmemorial.com.

MEMBERS:

Cameron Berg, MD	Leslie Baken, MD	Nicholas Davis, MD	Umair Ahmed, MD
Jacob Reynolds, MD	Jennifer Marquart, PharmD	Joseph Sicora, MD	Sarah Johnson, PharmD
Emily Herstine, PharmD	Peter Yawn, MD	Kayla Carson	Paul Krogh, PharmD

If you would like further information about Clinical Programs and Integration, please contact the Medical Director of Quality,

Jeffrey Vespa, MD— Jeffrey.Vespa@NorthMemorial.com or Anna Rees, Manager— Anna.Rees@NorthMemorial.com